198 related articles for article (PubMed ID: 34592434)
1. Searching for an ideal SERM: Mining tamoxifen structure-activity relationships.
Price S; Bender SG; Yahn R; Till NA; Varady S; LaLonde RL
Bioorg Med Chem Lett; 2021 Nov; 52():128383. PubMed ID: 34592434
[TBL] [Abstract][Full Text] [Related]
2. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Peng J; Sengupta S; Jordan VC
Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
[TBL] [Abstract][Full Text] [Related]
3. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
Park WC; Jordan VC
Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.
Fan P; Craig Jordan V
Steroids; 2014 Nov; 90():44-52. PubMed ID: 24930824
[TBL] [Abstract][Full Text] [Related]
6. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
Ball LJ; Levy N; Zhao X; Griffin C; Tagliaferri M; Cohen I; Ricke WA; Speed TP; Firestone GL; Leitman DC
Mol Cell Endocrinol; 2009 Feb; 299(2):204-11. PubMed ID: 19059307
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen to raloxifene and beyond.
O'Regan RM; Jordan VC
Semin Oncol; 2001 Jun; 28(3):260-73. PubMed ID: 11402436
[TBL] [Abstract][Full Text] [Related]
8. Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
Terakawa N
Oncology; 2000; 59 Suppl 1():3-4. PubMed ID: 11096349
[No Abstract] [Full Text] [Related]
9. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Gajdos C; Jordan VC
Clin Breast Cancer; 2002 Jan; 2(4):272-81. PubMed ID: 11899358
[TBL] [Abstract][Full Text] [Related]
10. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
[TBL] [Abstract][Full Text] [Related]
11. Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
Eisen SF; Brown HA
Mol Pharmacol; 2002 Oct; 62(4):911-20. PubMed ID: 12237338
[TBL] [Abstract][Full Text] [Related]
12. Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.
Cerrato F; Fernández-Suárez ME; Alonso R; Alonso M; Vázquez C; Pastor O; Mata P; Lasunción MA; Gómez-Coronado D
Br J Pharmacol; 2015 Mar; 172(5):1379-94. PubMed ID: 25395200
[TBL] [Abstract][Full Text] [Related]
13. Progress in the prevention of breast cancer: concept to reality.
Jordan VC
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):269-77. PubMed ID: 11162935
[TBL] [Abstract][Full Text] [Related]
14. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: estrogen receptor dependent or independent pathways of raloxifene.
Miki Y; Suzuki T; Nagasaki S; Hata S; Akahira J; Sasano H
J Steroid Biochem Mol Biol; 2009 Feb; 113(3-5):281-9. PubMed ID: 19429434
[TBL] [Abstract][Full Text] [Related]
16. The immune activity of selective estrogen receptor modulators is gene and macrophage subtype-specific yet converges on Il1b downregulation.
Sfogliarini C; Pepe G; Cesta CM; Allegretti M; Locati M; Vegeto E
Biomed Pharmacother; 2023 Sep; 165():115008. PubMed ID: 37442065
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Jordan VC; O'Malley BW
J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
[TBL] [Abstract][Full Text] [Related]
18. Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.
McDonnell DP; Wardell SE; Norris JD
J Med Chem; 2015 Jun; 58(12):4883-7. PubMed ID: 26039356
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting in the estrogen receptor hormonal pathway.
Katzenellenbogen BS; Frasor J
Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
